In the DUKE cohort, the prediction results of HER2+ and ER/PR+&HER2− also improved after correction, but the performance in triple-negative breast cancer was poor, potentially because these tumors have strong heterogeneity and are challenging to evaluate.28 This evidence concerns the gene ESR1 and triple-negative breast carcinoma.